Maze Therapeutics (NASDAQ:MAZE) Raised to “Hold” at Wall Street Zen

Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Several other equities research analysts have also issued reports on the company. BTIG Research raised their target price on Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Raymond James Financial started coverage on shares of Maze Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price objective for the company. HC Wainwright lifted their price objective on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, December 3rd. Finally, Wedbush increased their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $44.50.

Maze Therapeutics Stock Down 4.2%

Shares of NASDAQ MAZE opened at $44.27 on Friday. The company has a market capitalization of $2.13 billion and a PE ratio of -2.12. The stock’s 50 day moving average price is $39.90 and its 200-day moving average price is $28.06. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $47.36.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Insider Buying and Selling

In other Maze Therapeutics news, CMO Harold Bernstein sold 25,156 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $40.20, for a total transaction of $1,011,271.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the transaction, the insider owned 10,503 shares of the company’s stock, valued at $426,001.68. The trade was a 87.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 167,500 shares of company stock valued at $6,774,667.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC purchased a new position in Maze Therapeutics during the second quarter worth about $28,000. Ameritas Investment Partners Inc. boosted its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Maze Therapeutics during the third quarter worth about $52,000. Finally, Legal & General Group Plc increased its position in shares of Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after purchasing an additional 3,371 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.